Conference Correspondent

Conference Correspondent

In a phase 1 study, the mIDH2 inhibitor enasidenib showed promise as a potential emerging therapy for patients with relapsed or refractory acute myeloid leukemia (AML).

Synthetic control arms may represent an efficient, cost-effective way to evaluate early end points in clinical trials.

Building on the results of a prior study, the combination of sorafenib and 5-azacytidine demonstrates promise in the treatment of older patients with FLT3-ITD–positive acute myeloid leukemia.

In this analysis, minimal residual disease (MRD)-negative status in patients with acute myeloid leukemia (AML) translated into lower risk of relapse but not improved relapse-free survival or overall survival.

A recent analysis suggests that molecular response to gilteritinib may correlate with clinical response and improved overall survival.

Specific types of somatic mutations predicted improved relapse-free survival in patients with acute myeloid leukemia (AML) achieving complete remission.

Results from a large database analysis revealed that a number of risk factors may independently contribute to overall survival in acute myeloid leukemia (AML).

Although idarubicin and cytarabine in combination with clofarabine or fludarabine have similar response profiles in patients with newly diagnosed acute myeloid leukemia (AML), differences in survival were seen between the 2 groups in younger patients.

Variability in surface antigen expression patterns correlated to different outcomes in patients with normal karyotype acute myeloid leukemia (AML).

Timed sequential administration of busulfan may represent a more efficacious approach to the treatment of patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Page 7 of 12
Results 61 - 70 of 111
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME